FIELD: medicine.
SUBSTANCE: substance of the invention includes a stable aqueous pharmaceutical composition containing monoclonal antibody natalizumab as an antibody, phosphate buffer, polysorbate and sodium chloride, pH 6.0±0.5.
EFFECT: stable aqueous formulation of natalizumab.
31 cl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| PHARMACEUTICAL COMPOSITION OF FUSION PROTEIN TACI-FC | 2020 |
|
RU2779387C1 |
| STABLE COMPOSITIONS OF ANTIGENS Neisseria meningitidis rLP2086 | 2011 |
|
RU2580620C2 |
| STABLE ISOTONIC LYOPHILIZED PROTEIN COMPOSITION | 1996 |
|
RU2229288C2 |
| PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
| DRUG FORM FOR hGH AND rhIGF-1 COMBINATION+ | 2010 |
|
RU2558821C2 |
| STABLE ISOTONIC LYOPHILISED PROTEIN COMPOSITION | 1996 |
|
RU2497500C2 |
| STABLE LIQUID COMPOSITION OF FUSED PROTEIN WITH DOMAIN Fc IgG | 2016 |
|
RU2688679C1 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
Authors
Dates
2009-06-20—Published
2004-02-09—Filed